To assess anti-tumor responses of chemotherapy when combined with ICB in vivo, we screened 10 chemotherapeutics from different canonical classes in combination with anti‐CTLA‐4/anti‐PD-L1 antibodies in two murine mesothelioma models (Figures 1A, B). The gene discussed is CTLA4; the disease is neoplasm.